Healthcare Equipment and Supplies
Company Overview of Veracyte, Inc.
Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2006
Key Executives for Veracyte, Inc.
Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.
Veracyte, Inc. Key Developments
Veracyte, Inc. Initiates Launch of Percepta™ Bronchial Genomic Classifier to Improve Lung Cancer Diagnosis
Apr 16 15
Veracyte, Inc. announced the launch of its Percepta™ Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country. The Percepta test is designed to reduce the number of invasive biopsies and other procedures that can follow when suspicious lung nodules are found on computerized tomography (CT) scans. The test is used when results from a bronchoscopy - a common nonsurgical procedure to evaluate lung nodules - are non-diagnostic, meaning that cancer cannot be ruled out. Data from a prospective, multicenter clinical validation study previously demonstrated the Percepta test's ability to identify patients whose lung nodules are at low risk of malignancy so that they can be monitored with CT scans in lieu of invasive diagnostic procedures. Veracyte's test comprises a 23-gene molecular classifier that uses proprietary "field of injury" technology to detect molecular changes that occur in the epithelial cells lining the lung's respiratory tract in response to smoking - the cause of 85-90% of lung cancers. These changes can be detected in cells obtained from standard cytology brushings taken during bronchoscopy from the proximal airway, and indicate the presence of malignancy or disease processes from distant sites in the lung.
Veracyte, Inc. and GE Announce Research Collaboration
Apr 14 15
Veracyte, Inc. and GE announced a research collaboration to develop new solutions that can improve disease diagnosis. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.
Veracyte, Inc. Announces Executive Changes
Apr 7 15
Veracyte, Inc. announced that in connection with his appointment as Senior Vice President, Strategic Finance and Operations, on April 6, 2015, Duncan T. Powell ceased to serve as the Principal Accounting Officer. Also on April 6, 2015, the Board of Directors of the company appointed Shelly D. Guyer, the company's Chief Financial Officer, to serve in the additional position of principal accounting officer. Ms. Guyer has served as the company's Chief Financial Officer since April 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions